Livedoid Vasculopathy: an Updated Review
- 40 Downloads
Purpose of Review
To highlight the most recent findings in the literature on livedoid vasculopathy while providing a basic review of the disease.
Lipoprotein(a) and plasminogen activator inhibitor continue to develop evidence supporting their involvement in the pathogenesis of livedoid vasculopathy. Systematic review of the literature has revealed that anticoagulants are the most commonly reported treatments in case series followed by anabolic steroids, antiplatelets, and intravenous immunoglobulins. No randomized or controlled trials have been performed studying treatment efficacy.
The literature continues to support the hypothesis that livedoid vasculopathy is a disease of hypercoagulability and impaired fibrinolysis. There is no established treatment for livedoid vasculopathy, although a wide variety of treatments have been used to achieve partial or complete remission. Anticoagulants continue to be the most commonly reported treatment in the literature with rivaroxaban used most frequently.
KeywordsLivedoid Vasculopathy Atrophie Blanche Treatment
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 11.Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005;3(8):1879–83.Google Scholar
- 12.Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract. 2005;59(1):102–6.Google Scholar
- 20.Yong AA, Tan AW, Giam YC, Tang MB. Livedoid vasculopathy and its association with factor V Leiden mutation. Singap Med J. 2012;53(12):e258–60.Google Scholar
- 21.Kavala M, Kocaturk E, Zindanci I, Turkoglu Z, Altintas S. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin. J Dermatol Treat. 2008;19(2):121–3.Google Scholar
- 23.• Weishaupt C, Strolin A, Kahle B, et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol. 2016;3(2):e72–9. One of the largest case series studying rivaroxaban efficacy in livedoid vasculopathy. Found improvement in pain, ulceration, and quality of life with minimal side effects with rivaroxaban. PubMedGoogle Scholar
- 28.Rampf J, Sunderkotter C, Hirschfeld G, Scharffetter-Kochanek K, Weiss JM. Methylenetetrahydrofolate reductase polymorphism associated with moderate hyperhomocysteinaemia in a patient with livedo vasculopathy: treatment with vitamin supplementation and low molecular weight heparin. Br J Dermatol. 2006;155(4):850–2.PubMedGoogle Scholar
- 36.Anavekar NS, Kelly R. Heterozygous prothrombin gene mutation associated with livedoid vasculopathy. Aust J Dermatol. 2007;48(2):120–3.Google Scholar
- 40.Nikolova K, Popov J, Obreshkova E. Leg ulcerations due to livedo vasculitis: successful combined therapy with pentoxifylline and nifedipine. J Eur Acad Dermatol Venereol. 1995;5:54–8.Google Scholar
- 79.Reagin H, Marks E, Weis S, Susa J. Livedoid vasculopathy presenting in a patient with sickle cell disease. Am J Dermatopathol. 2018:1.Google Scholar
- 81.• Agirbasli M, Goktay F, Peker I, Gunes P, Aker FV, Akkiprik M. Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions. Cardiovasc Ther. 2017;35(3) This study found significantly increased plasminogen activator inhibitor-1 gene expression in livedoid vasculopathy lesions relative to controls suggesting its role in the pathogenesis of livedoid vasculopathy. Google Scholar
- 83.• Espinel D, Di Giacomo TB, Pincelli TP, et al. Analysis of serum levels and cutaneous expression of lipoprotein (a) in 38 patients with livedoid vasculopathy. J Cutan Pathol. 2017;44(12):1033–7. This study found a 10-fold higher expression of lipoprotein(a) immunostaining in the skin lesions and elevated serum levels of this protein in livedoid vasculopathy patients relative to controls, suggesting its role in the pathogenic mechanism of livedoid vasculopathy. PubMedGoogle Scholar
- 86.Hesse G, Kutzner H. Niedermolekulares heparin zur therapie der ulzerierten capillaritis alba. Phlebologie. 2008;37(5):259–65.Google Scholar
- 89.• Micieli R, Alavi A. Treatment for livedoid vasculopathy: a systematic review. JAMA Dermatol. 2017; Systematic review of case series studying treatment efficacy in livedoid vasculopathy. To date, only case series and case reports have studied management of livedoid vasculopathy. Anticoagulants were the most commonly reported treatment. Google Scholar
- 100.Herskovitz I, Jaller J, Kirsner R. Two successful cases of combination therapy with rivaroxaban and stanozolol for livedoid vasculopathy. JAAD. 2017;76(6):AB272.Google Scholar
- 127.Furukawa F, Mizawa M, Makino T, Shimizu T. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy. BMJ Case Rep. 2017;2017Google Scholar
- 129.Gonzalez-Santiago TM, Davis MD. Update of management of connective tissue diseases: livedoid vasculopathy. Dermatol Ther. 2012;25(2):183–94.Google Scholar
- 130.Zampeli E, Moutsopoulos HM. Livedoid vasculopathy. Arthritis Rheum. 2017;69(10):2096.Google Scholar
- 133.den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334(12):759–62.Google Scholar